<div id = "firstBodyDiv" data-bind-html-content-type = "article" data-bind-html-compile = "article.body" data-first-article-body = "
According to “Sky News”, Oxford scientists are proceeding with tests very quickly about this promising treatment, in a project separate from the vaccine, to help treat the most affected by the coronavirus, especially the elderly, and those who suffer from weak immune systems, which may Effectively affects their body’s response to any possible vaccine.
The CEO of the drug giant Astra Zenica, which cooperates with Oxford scientists in the production of vaccine and antibody therapy, Pascal Suryot, described the promising antibody treatment as a “combination of two antibodies”, in a single dose, that may reduce the opportunity to develop The person is against the resistance of one of them, according to statements by the British Telegraph.
However, although antibody therapy may be vital and effective for some groups, Suryot confirms that vaccine production against the virus remains a priority.
The CEO of the drug giant says the cost of producing a potential antibody treatment is much higher than the cost of producing vaccines.
And AstraZeneca signed a contract with the University of Oxford to produce millions of doses of the possible vaccine for the virus, if it was proven to be effective.
Oxford scientists confirmed earlier that they are confident of the effectiveness of the vaccine they are developing, at a time when the clinical trials of the vaccine continue, in Britain as well as Brazil, with the high rate of infections in this country at the present time.
Results on this vaccine are expected to appear by next July, according to Suryot.
British officials confirm that 30 million doses of the Covid 19 vaccine will be available in Britain by next September, despite some scientists’ doubts about the possibility of providing effective vaccines soon.
“>
According to “Sky News”, Oxford scientists are proceeding with tests very quickly about this promising treatment, in a project separate from the vaccine, to help treat the most affected by the coronavirus, especially the elderly, and those who suffer from weak immune systems, which may Effectively affects their body’s response to any possible vaccine.
The CEO of the drug giant Astra Zenica, which cooperates with Oxford scientists in the production of vaccine and antibody therapy, Pascal Suryot, described the promising antibody treatment as a “combination of two antibodies”, in a single dose, that may reduce the opportunity to develop The person is against the resistance of one of them, according to statements by the British Telegraph.
However, although antibody therapy may be vital and effective for some groups, Suryot confirms that vaccine production against the virus remains a priority.
The CEO of the drug giant says the cost of producing a potential antibody treatment is much higher than the cost of producing vaccines.
And AstraZeneca signed a contract with the University of Oxford to produce millions of doses of the possible vaccine for the virus, if it was proven to be effective.
Oxford scientists confirmed earlier that they are confident of the effectiveness of the vaccine they are developing, at a time when the clinical trials of the vaccine continue, in Britain as well as Brazil, with the high rate of infections in this country at the present time.
Results on this vaccine are expected to appear by next July, according to Suryot.
British officials confirm that 30 million doses of the Covid 19 vaccine will be available in Britain by next September, despite some scientists’ doubts about the possibility of providing effective vaccines soon.
– .
